Clinical Trial Update: Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated the combination of inotuzumab ozogamicin with rituximab in patients with diffuse large B-cell lymphoma. The trial has completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Inotuzumab ozogamicin (inotuzumab ozogamicin)
• Rituximab (rituximab)

Snippet

Sponsor: Pfizer | Conditions: Lymphoma, B-Cell | Phase 2 | Status: COMPLETED | Results posted: 2017-08-22